Cormorant Asset Management LP 13D and 13G filings for Olema Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 3:08 pm Purchase |
2023-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 2,456,800 4.490% |
374,800 (+18.00%) |
Filing |
| 2023-02-14 3:08 pm Sale |
2022-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 2,082,000 5.150% |
-87,871 (-4.05%) |
Filing |
| 2022-02-14 3:01 pm Sale |
2021-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 2,169,871 5.390% |
-1,025,673 (-32.10%) |
Filing |
| 2021-02-16 3:24 pm Sale |
2020-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 3,195,544 7.960% |
-75,000 (-2.29%) |
Filing |
| 2020-11-23 4:59 pm Purchase |
2020-11-23 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 3,270,544 8.140% |
3,270,544 (New Position) |
Filing |